Vericel

NMQ:VCEL · US92346J1088

BiotechnologyMedium

360

Value46

Profit price10

EV / EBIT19

Price / Owner Earnings1

Cash yield44

Owner Earnings Yield86

Dividend Yield1

Sales & asset price46

Price/Sales55

EV / Gross Profit57

Price/Book26

Quality72

Returns on capital87

Return on Capital84

Cash Return on Capital89

Return on Equity89

Profit margins77

EBIT Margin67

Gross Profitability87

Cash backing67

Accruals46

Owner Earnings Margin87

Growth53

Sales growth62

Profit growth54

Profit Growth57

Long-Term EPS Growth51

Reinvestment7

Price momentum30

Safety57

Debt load41

Debt serviceability95

Refinancing90

Debt Payback100

Liquidity87

Sentiment55

Analyst ratings65

Expectations trend39

Opinion Changes50

Price Target Upside28

Market mood83

Value Creation14/20strong value creator

Creates more value than its capital costs
Owner earnings growing
Owner earnings per share growing
Reinvests at strong returns
Solid earnings base

What this means

Vericel generates returns well above its cost of capital, the foundation of durable shareholder value.

Profile

CountryUSA

IndustryBiotechnology

SizeMedium

TypePublic Company

ExchangeNASDAQGM

Founded1989

Employees451

Websitevcel.com

ISINUS92346J1088

Last UpdateApr 2, 2026

Indices

NASDAQ (USA)

Themes

Pain ManagementStem Cell TherapyBiomedical EngineeringOrthopaedicsSurgeryBiotechnologyLife ScienceTherapeutics

Description

Vericel Corporation operates as a fully-integrated, commercial-stage biopharmaceutical company. The company provides advanced therapies for the sports medicine and severe burn care markets. The company has a highly differentiated portfolio of cell t…

Analysis

Quality compounder

Vericel Corporation earns the quality_compounder label: good underlying economics priced fairly, with no obvious bargain or excess.

On valuation, the picture is expensive. The owner-earnings multiple stands at 101.3×; owner earnings: the cash an owner could take out each year.

Growth is moderate; the safety picture is adequate. The company scores 14/20 on our value-creation score: strong value creator.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250

2026

All-time high

Jun 2026

All-time low

Mar 2026

Average rank

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Vericel with its peers

MIRA Pharmaceuticals

NAQ:MIRA

—

CountryUSA

IndustryPharmaceuticals

SizeX-Small

Full Stock Analysis →

Abeona Therapeutics

NAQ:ABEO

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Ocular Therapeutix

NMQ:OCUL

CountryUSA

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Harmony Biosciences Holdings

NMQ:HRMY

CountryUSA

IndustryPharmaceuticals

SizeMedium

Full Stock Analysis →

Journey Medical Corporation

NAQ:DERM

CountryUSA

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Eledon Pharmaceuticals

NAQ:ELDN

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →